Does RELATLIMAB Cause Malignant neoplasm progression? 9 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Malignant neoplasm progression have been filed in association with RELATLIMAB. This represents 5.1% of all adverse event reports for RELATLIMAB.
9
Reports of Malignant neoplasm progression with RELATLIMAB
5.1%
of all RELATLIMAB reports
7
Deaths
7
Hospitalizations
How Dangerous Is Malignant neoplasm progression From RELATLIMAB?
Of the 9 reports, 7 (77.8%) resulted in death, 7 (77.8%) required hospitalization, and 1 (11.1%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RELATLIMAB. However, 9 reports have been filed with the FAERS database.
What Other Side Effects Does RELATLIMAB Cause?
Pneumonia (13)
Myocarditis (8)
Hypotension (7)
Meningitis aseptic (7)
Pyrexia (7)
Sepsis (7)
Adrenal insufficiency (6)
Drug ineffective (6)
Hepatitis (6)
Myositis (6)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which RELATLIMAB Alternatives Have Lower Malignant neoplasm progression Risk?
RELATLIMAB vs RELPAX
RELATLIMAB vs RELUGOLIX
RELATLIMAB vs REMDESIVIR
RELATLIMAB vs REMERON
RELATLIMAB vs REMICADE